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Background. A mass vaccination has been implemented to prevent the spread of 2009 pandemic inﬂuenza virus
in China. Highly limited information is available on whether this vaccine induces cross-reactive neutralization
antibodies against other subtypes of inﬂuenza viruses.
Methods. We employed pseudovirus-based assays to analyze heterosubtypic neutralization responses in serum
samples of 23 recipients of 2009 pandemic inﬂuenza vaccine.
Results. One dose of pandemic vaccine not only stimulated good neutralization antibodies against cognate
inﬂuenza virus 2009 inﬂuenza A (H1N1), but also raised broad cross-reactive neutralization activities against
seasonal H3N2 and highly pathogenic avian inﬂuenza virus H5N1 and lesser to H2N2. The cross-reactive
neutralization activities were completely abolished after the removal of immunoglobin G (IgG). In contrast, H1N1
vaccination alone in inﬂuenza-naive mice elicited only vigorous homologous neutralizing activities but not cross-
reactive neutralization activities.
Conclusions. Our data suggest that the cross-reactive neutralization epitopes do exist in this vaccine and could
elicit signiﬁcant cross-reactive neutralizing IgG antibodies in the presence of preexisting responses. The exposure to
H1N1 vaccine is likely to modify the hierarchical order of preexisting immune responses to inﬂuenza viruses. These
ﬁndings provide insights into the evolution of human immunity to inﬂuenza viruses after experiencing multiple
inﬂuenza virus infections and vaccinations.
In 2009, a new pandemic H1N1 inﬂuenza virus with
a combination of gene segments derived from North
American and Eurasian swine lineages was identiﬁed
[1, 2]. Worldwide mass vaccination has been imple-
mented to prevent its spread and to reduce illness and
death from this pandemic inﬂuenza. Several lines of
evidences were reported on the safety, immunogenicity,
and protection effectiveness of this vaccine [3–5]. How-
ever, very limited information is available on how the
vaccine inﬂuences on immune responses to concomitant
seasonal or highly pathogenic avian inﬂuenza viruses that
also have posed considerable threads to public health.
Therefore, we initiated experiments to investigate the
neutralization activities to heterosubtypic inﬂuenza vi-
ruses in serum samples collectedfrom the recipients ofthe
2009 pandemic H1N1 inﬂuenza vaccine.
MATERIALS AND METHODS
Participants and Serum Samples
Twenty-three employees of Shanghai Public Health Clin-
ical Center (SHAPHC) received 1 dose (15 lg/0.5 mL) of
unadjuvanted inactivated split of 2009 pandemic in-
ﬂuenza vaccine (vaccine strain was A/California/07/2009,
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oculation on 15 October 2009. Participants in this study were
conﬁrmed for the absence of inﬂuenza illness in the last 3 months
before vaccination. Pregnant and lactating women were also ex-
cluded. Table 1 shows the demographic proﬁles of participants,
composed of 18 women and 5 men, born between 1952 and 1989.
The baseline samples were collected on the day of and just prior to
vaccine administration. The samples of postvaccination were
collected on the 21st day after vaccine administration. Written
informed consents were obtained from all participants. The
overall study was reviewed and proved by the Ethics Committee of
SHAPHC.
Mouse Immunization Protocol
Six mice bred under speciﬁc-pathogen-free (SPF) circumventions
were immunized with 100 lg DNA vaccine expressing HA of
pandemic inﬂuenza (A/Texas/05/2009[H1N1], designated TE09
H1) by intramuscular route at a 2-week intervals for 4 times, and
an additional 6 mice were immunized with 100 lgs h a mD N Aa s
the mock control group. Serum samples were collected 2 weeks
after the ﬁnal immunization and combined by group for the
neutralization assay, which ensured a sufﬁcient volume of serum
samples for different pseudovirus and serial dilution.
Hemagglutination-Inhibition Assays
Serum samples were treated with receptor-destroying enzyme
(RDE) to inactivate nonspeciﬁc inhibitors, and then serially
diluted 2-fold into U-bottom 96-well microtiter plates, starting
with 1:10 and stopping at 1:1280, in a volume of 50 lL. The
hemagglutination-inhibition (HI) titer was determined by the
reciprocal of the last dilution that contained nonagglutinated
red blood cells. Serum from a 2009 H1N1 infected but recovered
subject was used as a positive control, and serum from a naive
mouse raised under speciﬁc pathogen-free circumventions was
used as a negative serum control. Samples with HI titers $1:40
were considered as seropositive. The virus strain used was
A/Shanghai/37T/2009(H1N1) (SH37T; GenBank accession:
ACS27776ACS27785), which shares 99.29% homogeneity of
hemagglutinin (HA) protein sequence (mutations are P100S,
S220T, I338V, and V428I) to A/California/07/2009 (GenBank
accession: ACP41953; Table 1; online only).
Generation of Influenza HA/Neuraminidase Pseudotyped
Lentivirus
4.5310
6 293T packaging cells were cotransfected with 5 lg
lentivirus vector pNL4-3.Luc.R-E-, 2.5 lg pVKD-HA, and
2.5 lg pVKD-NA using Lipofectamine 2000 from Invitrogen
(Frederick, MD). The HA sequences were humanized from 2009
pandemic inﬂuenza TE09 H1 (GenBank accession: ACP41934);
seasonal inﬂuenza viruses, including A/Brisbane/59/2007(H1N1)
(designated as BR07 H1, GenBank accession: ACA28844), A/
Singapore/6/1986(H1N1) HA (designated as SI86 H1, GenBank
No. ABO38395), A/Japan/305/57(H2N2) (designated as JA57 J2,
GenBank accession: AAT66416.1), and A/Moscow/10/
1999(H3N2) (designated as MO99 H3, GenBank accession:
AAT08002); and highly pathogenic avian inﬂuenza A/Viet Nam/
1203/2004(H5N1) (designated as VN04 H5, GenBank accession:
AAW80717). The sequence of neuraminidase (NA) was derived
from A/Shanghai/37T/2009(H1N1) (designated as SH37T,
GenBankaccession:ACS27784).After overnight incubation, cells
were washed once with PBS and cultured in 5 mL complete
Dulbecco’s modiﬁed Eagle’s medium (DMEM). The pseudotype
viruscontaining supernatants were harvested in 16–20 hoursand
stored at 280C in aliquots until used in a neutralization assay.
The phylogenetic tree of the amino acid sequences of HAs used
in HI and the pseudotyped virus assays are shown in Supple-
mentary Figure 1 (online only).
Removal of Immunoglobin G
Four serum samples with highest cross-reactive neutralization ac-
tivities against VN04 H5 were selected for the depletion of im-
munoglobin G (IgG). IgG was removed using Protein G Sepharose
Beads. Brieﬂy, 200 lL Protein G Sepharose Beads was washed
3 times with ice-cooled phosphate-buffered saline (PBS). At the
ﬁnal wash, the supernatant was aspired after centrifuging, and
100 lL pooled serum was added. The serum-beads mixture was
Table 1. Demographic Information of Study Participants and
Their Hemagglutination-Inhibition Titers Pre- and Postvaccination
Subject
no.
Year
of
birth Gender
HI titer
Prevaccination Postvaccination
34 1952 female 10 20
30 1955 female 40 80
2 1960 male 20 640
148 1961 female 20 80
32 1965 male 40 160
130 1968 female 10 640
36 1969 female 10 80
40 1971 female 20 640
24 1975 female 5 320
28 1976 female 5 80
15 1977 female 10 1280
51 1977 male 20 640
10 1979 female 20 320
41 1979 female 5 320
29 1981 female 5 40
120 1981 female 80 320
127 1981 male 5 20
93 1982 female 40 320
121 1982 female 5 160
9 1983 male 40 80
39 1987 female 10 160
35 1989 female 10 40
123 1989 male 5 20
Abbreviation: HI, hemagglutination-inhibition.
18 d CID 2012:54 (1 January) d Qiu et alincubated at 4C under rotary agitation for 1 hour, centrifuged,
and the supernatant was kept as IgG-depleted serum. All steps
were repeated 3 times to remove abundant IgG.
Pseudotype-Based Neutralization Assay
Humanserum samples or IgG-depleted serum samples were 2- or
3-fold serially diluted and incubated with indicated amounts of
pseudotyped virus at the ﬁnal volume of 150 lLa t3 7 Cf o r
1 hour, then the mixture was added to cultures of Madin-Darby
canine kidney (MDCK) cells. After overnight incubation, cells
were then washed with PBS and cultured in complete DMEM for
48 hours. Luciferase activity (RLA) was measured by a BrightGlo
Luciferase assay according to the manufacturer’s instruction
(Promega, Madison, WI). In the assay, the neutralizing titer of
human serum samples was calculated according to the inhibition
of MDCK cells by the pseudotyped viruses’ infection. Inhibition
percentage was calculated as follows: (RLA in medium control –
RLA in serum at a given dilution)/RLA in medium control. The
50%inhibitory concentration (IC50) was reported as the dilutions
of a given serum that resulted in a 50% reduction of RLA. For
a pseudovirus-based assay, ,50% inhibition was considered as
negative, and the ﬁnal dilution of serum samples able to reach
$50% inhibition was considered as the serum sample titer. For
mice experiments, serum samples collected 2 weeks after the ﬁnal
immunization and combined by group were used in the neu-
tralizing activity test.
Statistical Analysis
Geometric mean titers (GMTs) were calculated by assigning a titer
of 5 to samples with no detectable HI antibodies at the starting
dilution (titer , 10). Wilcoxon signed rank test was used to cal-
culate P value when compared with GMT between paired data.
Pearson product moment correlation was used to calculate the
correlation. Figures were plotted using GraphPad Prism software.
RESULTS
Antibody Responses to the Homologous Pandemic H1N1
Influenza Virus
We evaluated the immunogenicity of the pandemic H1N1 in-
ﬂuenza vaccine in recipients. As expected, 18 of 23 participants
displayed undetectable or low levels of HI antibodies against the
homologous pandemic H1N1 inﬂuenza virus before immuni-
zation,whereas theother5 participantshadalevelofHIwiththe
titer higher than 40, though they reported no inﬂuenza illness or
symptoms in the last 3 months (Table 1). Consistent with other
reports, the HI titer signiﬁcantly increased in all participants
with a varied extent on day 21 post vaccination (GMT 13.12 vs
150.6, P , .0001,Table 1), and 87.0% (20 out of 23) participants
h a dat i t e rh i g h e rt h a n4 0[ 3, 5].
We also employed a more sensitive neutralization assay,
a luciferase and pseudovirus–based assay, to measure the
neutralization activity against the pandemic H1N1 inﬂuenza vi-
rus. Unexpectedly, we observed signiﬁcant neutralization activities
in the serum samplesof 20subjects at the baseline (Figure 1A,g r a y
bar). Since all participants had no exposure history to 2009 in-
ﬂuenza A (H1N1), it is likely those neutralization activities re-
sulted from cross-reactive antibodies developed during previous
exposure to other inﬂuenza virus infection. This observation may
explain why the majority of 2009 inﬂuenza A (H1N1) infections
were manifested as subclinical infection. Interestingly, despite the
presence of signiﬁcant cross-reactive neutralization activities, 1
dose of 2009 H1N1 vaccine resulted in a signiﬁcant increase of
neutralization activitiesin21 outof 23 volunteers (Figure 1A,d a r k
bar). The total neutralization activities (IC50) were closely asso-
ciated with total HI titers (Figure 1B), and the increase of IC50
from baseline was also correlated to the increase of HI titers from
t h eb a s e l i n e( F i g u r e1 C), indicating that these 2 assays are com-
parable and the pseudovirus-based assay is reliable.
Overall, our data proved that the pandemic H1N1 inﬂuenza
vaccine is immunogenic, and is able to elicit both HI and neu-
tralization antibodies.
2009 Pandemic Influenza Vaccine Boosts Cross-reactive
Responses to Other Subtypes of Influenza Viruses
We next evaluated whether the neutralization antibodies elicited
by the 2009 pandemic vaccine had an impact on other inﬂuenza
Figure 1. Homologous immune responses in serum samples of 2009
pandemic vaccine recipients. Twenty-three volunteers received 1 dose of
2009 pandemic vaccine. Serum samples were collected before and
21 days after vaccination. A, The individual IC50 titers (reciprocal 50%
inhibitory concentration) before (gray) and after (dark) vaccination.
B, Correlation between the IC50 titers and hemagglutination-inhibition (HI)
titers in serum samples post vaccination. C, Correlation between the
increase of HI titer from baseline (HI post – HI pre) and the change in
magnitude of IC50 titer from baseline (IC50 post – IC50 pre).
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against heterosubtypes H1N1, H2N2, H3N2, and H5N1. We
ﬁrst tested the neutralization activities against HA pseudoviruses
derived from the contemporary human seasonal inﬂuenza A vi-
ruses, including BR07 H1 and MO99 H3. Remarkably, the
baseline serum samples already had very high neutralization titers
to these 2 seasonal inﬂuenza viruses, indicating that prior in-
fection or vaccination imprint e dt h ei m m u n es y s t e ma n dd e -
veloped the preexisting immunity. Again, despite the presence of
high neutralization activities against MO99 H3, the IC50 titers
increased markedly in 11 of21 participants following vaccination,
whereas only 2 out of 10 subjects increased their titers to BR07
H1. In addition, the IC50 titers to MO99 H3 in postvaccination
serum samples were signiﬁcantly correlated with the titer of HI to
TE09 H1. Furthermore, the increases of IC50 titers to MO99 H3
from baseline were also signiﬁcantly correlated to the increases of
HI titers to TE09 H1 from the baseline (Figure 2A and 2B). These
data indicate that 2009 pandemic vaccine boosted cross-reactive
responses to seasonal inﬂuenza MO99 H3 but not BR07 H1.
We next tested whether the vaccine-elicited neutralization an-
tibodieswere capable of cross-reacting to JA57 H2, avirusthat led
to the epidemic of Asian inﬂuenza in Japan that began in May
1957 [6]. Unexpectedly, the neutralization activities against
JA57 H2 were elevated in half of recipients following vaccination;
however, the neutralization activities against this H2 were re-
versely associated with HI titers to TE09 H1, though it did not
reach statistical signiﬁcance (Figure 2C,m i d d l ep a n e l ) .T h e s ed a t a
may indicate that cross-reactive neutralization antibodies against
JA57 H2 may compete with HI responses to TE09 H1. In addi-
tion, we also quantiﬁed the cross-reactive neutralization activities
to highly pathogenic avian inﬂuenza VN04 H5. The H5 neu-
tralization activity was readily presented in prevaccination serum
samples at relatively lower titers compared with that for H3or H1.
Interestingly, following vaccination, the H5 neutralization activi-
ties were profoundly increased in 21 out of 23 vaccinees, and
signiﬁcant correlations were observed in both total titers and the
increase from the baseline in magnitude of IC50 with HI to
TE09 H1, indicating that the elevation of H5 neutralization ac-
tivity was attributed to the administration of the 2009 pandemic
vaccine (Figure 2D). However, no associations between the levels
of enhanced heterotypic neutralization activities and ages were
observed in this small group (data not shown).
Profound Decrease of Cross-reactive Neutralizing Activities
After the Depletion of IgG Antibodies
To understand the nature of this cross-reactivity, we determined
the cross-reactive neutralizing activities of the serum samples after
the depletion of IgG. Four serum samples, including subjects 15,
28, 32, and 36, were selected for the depletion as those samples
gave rise to the highest cross-reactive neutralization activities in
our above experiments. As expected, the depletion of IgG resulted
in a dramatic decrease in the neutralization activities against both
homologous TE09 H1 and heterosubtypic VN04 H5 to varied
extents (Table 2). Interestingly, while the cross-reactive neutrali-
zation activities against VN04 H5 were completely abolished after
the depletion of IgG, the neutralization activities against homol-
ogous TE09 H1 were only partially removed though a profound
decrease was observed in 3 out of 4 patients (Table 2). Surpris-
ingly, the neutralization activities remained intact in 1 patient
(subject 36) after the removal of IgG from serum samples al-
though the depletion had resulted in the complete removal of
cross-reactive neutralization activities against H5. In addition,
these observations coincided with the failure to enhance the
neutralization activities in this subject after vaccination with 2009
pandemic inﬂuenza vaccine. Overall, these data suggest that the
cross-reactive neutralization activities are largely mediated by IgG
antibodies, whereas homologous neutralization activities may be
mediated by both IgG and non-IgG antibodies.
Vaccination With 2009 Pandemic Influenza–Derived HA
Immunogen Mainly Elicited Homologous Neutralization
Antibodies in Influenza-Naive Mice
We proposed that the cross-reactive neutralization antibodies
observed at baseline were developed by the preexposure to sea-
sonal inﬂuenza A infection or vaccination, and the 2009 pan-
demic inﬂuenza vaccine (H1N1) might contain cross-reactive
neutralization epitopes, thereby enhancing the cross-reactive
neutralization activities against H5N1, H3N2, and H2N2. We
tested this hypothesis in mice models. SPF breeding mice naive
to inﬂuenza were vaccinated 4 times withDNA expressingHAof
2009 pandemic inﬂuenza H1N1, and neutralization activities to
different subtypes of inﬂuenza viruses were quantiﬁed in an
identical pseudovirus-based assay as described above. As shown
in Figure 3, there was no preexisting immunity to any subtype of
inﬂuenza in the mock control mouse. Unexpectedly, vigorous
neutralization activities were only observed against homologous
pseudovirus TE09 H1 in 2009 pandemic inﬂuenza vaccinated
serum samples, whereas only marginal activities were identiﬁed
for BR07 H1 and JA57 H2, and no detectable activities were
observed against SI86 H1, MO99 H3, and VN04 H5. These data
suggest that homologous neutralization epitopes are highly im-
munogenic in 2009 pandemic inﬂuenza vaccine (H1N1) and
thereby capable of raising vigorous neutralization antibodies,
whereas cross-reactive neutralization epitopes are too weak in
their immunogenicity to compete with homologous epitopes,
and fail to raise signiﬁcant cross-reactive neutralization activities
when this vaccine is administrated alone.
DISCUSSION
The outbreak of inﬂuenza is driven by coevolution between the
virus and human immunity. To prevent the outbreak of
20 d CID 2012:54 (1 January) d Qiu et alFigure 2. Cross-reactive neutralization activities to heterosubtypes of influenza viruses in serum samples of 2009 pandemic vaccine recipients.
Neutralization activities against A/Moscow/10/1999(H3N2) (A), A/Brisbane/59/2007(H1N1) (B), A/Japan/305/57(H2N2) (C), and A/Viet Nam/1203/
2004(H5N1) (D). Left, individual 50% inhibitory concentration (IC50) titers; middle, correlation between the hemagglutination-inhibition (HI) titers to
pandemic influenza and IC50 titers to tested virus in sera postvaccination; right, correlation between the increase of HI titers to pandemic influenza from
baseline and the change in magnitude of IC50 titers to tested virus.
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World Health Organization (WHO) yearly recommends as
vaccine candidates those strains most likely to emerge based on
surveillance of circulating viruses. But this strategy does not
always work, exempliﬁed by the outbreak of 2009 pandemic
inﬂuenza (H1N1). It only took 3 months for the newly emerged
virus to spread worldwide due to a lack of preexisting immunity
in a subpopulation, because recent seasonal inﬂuenza vaccines
induce little or no cross-reactive antibody responses to pan-
demic inﬂuenza [7]. Mass vaccination has been implemented to
prevent its further spread. To understand and prepare for in-
ﬂuenza epidemics, it is important to question what inﬂuences
the pandemic vaccine has on the immunity to seasonal or highly
pathogenic avian inﬂuenza viruses.
Here we report the effects of a pandemic vaccine on humoral
immune responses to other subtypes of inﬂuenza virus in vac-
cine recipients. The pandemic vaccine not only raises neutrali-
zation antibodies to cognate H1N1, but also elicits broadly
heterosubtypic neutralization responses—the implications of
which would affect recommendations regarding the composi-
tion of inﬂuenza vaccine immunogens. These ﬁndings are
consistent with the observation in pandemic virus–infected
patients [8]. We proposed from these data that cross-reactive
neutralization epitopes may exist in this vaccine and thereby has
the ability to raise broad cross-reactive neutralization antibodies
against different subtypes of inﬂuenza viruses. Unexpectedly,
when we tested this idea in mice experiments, we observed that
the inoculation of 2009 pandemic inﬂuenza HA alone was only
able to elicit high neutralization activities to cognate H1N1 vi-
rus, but only marginal neutralization activities were observed to
BR07 H1 and JA57 H2, and none were observed to SI86 H1,
MO99 H3, and VN04 H5. The observational discrepancy
between humans and mice may be explained by the different
neutralization activities at baseline, vigorous cross-reactive
neutralization activities were identiﬁed in human samples at
baseline, whereas no activities were detected in mouse samples
in the absence of vaccination, as shown in mock-control-
immunized mice. These data demonstrated that the preexist-
ing immunity, as observed in our study, plays an important
role in ﬁnalizing the composition of immunity, and that
the inoculation of the 2009 pandemic vaccine served as
a boost and was able to enhance the preexisting cross-reactive
neutralization activities but not for de novo cross-reactive
neutralization activities. In other words, the cross-reactive
neutralization epitopes do exist in the 2009 pandemic in-
ﬂuenza vaccine; their immunogenicity was only manifested in
the presence of their preexisting cross-reactive neutralizing
activities.
Existence of cross-reactive immunity between previous in-
ﬂuenza infections and the 2009 pandemic inﬂuenza has been
observed in several reports, and demonstrated that the pre-
exposure to 1918 pandemic inﬂuenza H1N1 or to 2007 seasonal
inﬂuenza H1N1 might have enhanced the cross-reactive neu-
tralizing antibodies against the 2009 pandemic inﬂuenza [9, 10].
Similarly, repeated infection with seasonal inﬂuenza viruses
improves protection and clearance of 2009 pandemic inﬂuenza
in ferrets[11]. Interestingly, vaccination with 1976 ‘‘swine ﬂu’’
coincided with the increased neutralizing activities against the
2009 pandemic inﬂuenza [7, 12]. In addition, immunization
with inactivated trivalent seasonal inﬂuenza vaccines induced
cross-reactiveneutralizing antibodies against the 2009 pandemic
inﬂuenza in humans [13] and against highly pathogenic H5N1
inﬂuenza virus in mice models [14]. The cross-reactive epitopes
may be less immunogenic, thus a potent adjuvant was re-
quired to manifest the cross-protective effect of an in-
activated H1N1 inﬂuenza vaccine against an H3N2 virus
[15]. A recent report demonstrated that it is widely prevalent
for the existence of heterosubtypic broadly neutralizing
human anti-inﬂuenza antibodies[16]. All these observations
together with our data largely support the veracity of the
hypothesis of original antigenic sin proposed by Thomas
Francis in 1960 [17], and the exposure to an inﬂuenza
strain distinct from the previous one not only resulted in
development of immunity to the current strain, but also
boosted the immune response to the previous virus strain;
therefore, the exposure history to different inﬂuenza viruses
dictates the hierarchy of cross-reactive immunity, which
greatlyemphasizes theimportance ofemploying mismatched
inﬂuenza HA immunogens for priming and boosting in or-
der to raise broad cross-reactive neutralization antibodies in
the context of a vaccine development strategy. However, the
phenomenon of original antigenic sin results in the compe-
tition between preexisting and newly developed immunity
Table 2. Profound Decrease of Cross-reactive Neutralizing
Activities After the Depletion of Immunoglobin G Antibodies
Virus strain Subject ID IgG1
a IgG–
b
TE09 H1
15 32805 1215
28 32805 405
32 32805 405
36 1215 1215
VN04 H5
15 2430 ,20
28 810 ,20
32 540 ,20
36 540 ,20
Abbreviations: IgG, immunoglobin G; TE09 H1, A/Texas/05/2009(H1N1);
VN04 H5, A/Viet Nam/1203/2004(H5N1).
a IgG1 indicates the serum samples containing IgG antibodies.
b IgG– indicates the IgG-depleted serum samples.
22 d CID 2012:54 (1 January) d Qiu et alandthereby attenuates the immuneresponsestocurrent viral
infection, and consequently may blunt the protection from
current inﬂuenza infection.
The preexisting cross-reactive neutralization antibodies raised
by preexposure to seasonal inﬂuenza viruses may explain why
the majority of 2009 inﬂuenza A (H1N1) infections were sub-
clinical infection in adult populations. Our data inform us that
the pandemic of inﬂuenza will not only inﬂuence the spread of
its cognate inﬂuenza virus but also the heterosubtypic inﬂuenza
virus. The understanding of cross-reactive inﬂuences between
inﬂuenzaviruseswillhelpustolearnaboutexistingimmunityin
populations, to predict the next possible wave of pandemic in-
ﬂuenza, and to gain new insight into established cross-reactive
neutralization immunity.
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Figure 3. Vaccination with 2009 pandemic influenza–derived hemagglutinin (HA) immunogen mainly elicited homologous neutralization antibodies
in influenza-naive mice. Six mice per group bred in specific pathogen-free environment received 43 DNA vaccine-expressing HA of pandemic
vaccine, or sham DNA as mock control group. Two weeks after final inoculation, serum samples were collected and combined by group. The
neutralization activities against homologous, seasonal, and highly pathogenic avian influenza viruses in both vaccinated mice (:) and mock-control
mice (D) were shown in serial 2-fold dilutions, triplicates were set for each dilution, and the mean value/standard error bar were used in plot. Less
than 50% inhibition was considered as negative, the final dilution of serum samples able to reach $50% inhibition was considered as the serum
sample titer. Since serum samples from 6 mice were combined for this assay, the value for each serum sample dilution represents the mean value
from 6 mice.
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